Current NHS post
Hampshire Hospitals NHS Foundation Trust, Basingstoke and University Hospital Southampton NHS Trust.
Training and education
- Undergraduate training, University of Cambridge and St George’s Hospital Medical School, 1989 to 1995.
- Membership of the Royal College of Physicians, 1998.
- Oncology training, pan-Thames training scheme, 1999 to 2006.
- Fellowship of the Royal College of Radiologists, 2003.
- MD, Royal Marsden Hospital and Institute of Cancer Research, 2003 to 2005.
Profile of Dr Andrew Jackson
Dr Jackson gained his CCST in clinical oncology in 2006 following training in London and took a post as a clinical lecturer and honorary consultant oncologist at The University of Manchester and Christie Hospital, specialising in upper gastrointestinal cancers, with additional academic interests in image-guided radiotherapy (IGRT) and imaging.
In 2010, Dr Jackson moved to University Hospital Southampton, with two days a week at Hampshire Hospitals NHS Foundation Trust.
He is continuing to pursue his research interest in upper gastrointestinal cancers.
- Radiotherapy technical lead, University Hospital Southampton.
- Chief investigator, ROCOCO (Radiotherapy and Olaparib in Combination for Oesophageal Cancer) phase 1 dose escalation study. Awarded funding by CRUK New Agents Committee, January 2011.
- Chief investigator, Biostent study (Biodegradable stents plus palliative radiotherapy for oesophageal cancer). Phase 2 study, awarded funding by NIHR Research for Patient Benefit program.
- Principal investigator, Christie Hospital, Manchester: PACER (Locally Advanced pancreatic cancer: Phase II study of Cetuximab and 3-D conformal Image Guided Radiotherapy). Three centres NCRN badged study.
- Co-investigator, Christie Hospital, Manchester: ‘A real-time visual feedback device for reducing patient movement during radiotherapy’, NIHR New and Emerging Applications of Technology (NEAT) award 2008.
Principal investigator, Christie Hospital, Manchester: DCE-MRI in oesophageal cancer: a pilot study. University of Manchester Magnetic Resonance Imaging Facility.
Awards and prizes
- Rohan Williams Medal for FRCR 2003.
Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol. 2014 Feb 1;7(1):55-64.
Parkhurst JM, Price GJ, Sharrock PJ, Jackson AS, Stratford J, Moore CJ. Self-management of patient body position, pose, and motion using wide-field, real-time optical measurement feedback: results of a volunteer study. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):904-10.
A Saleem, A. Jackson , S Mukherjee, N Stones, T Crosby, D Tait, P Price. Radiotherapy in the Management of Unresectable Locally Advanced Pancreatic Cancer: a Survey of the Current UK Practice of Clinical Oncologists. Clin Oncol (R Coll Radiol). 2010 May;22(4):257-60.
MT Guerrero Urbano, J Staffurth , A. Norman, FM Buffa, A Jackson, EJ Adams, V Hansen, C Clark, L Miles, H McNair, CM Nutting, C Parker, V Khoo, R Eeles, R Huddart, A Horwich, DP Dearnaley. Intensity Modulated Radiotherapy (IMRT) allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: Results of a phase 1 dose escalation study. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44.
ASN Jackson, P Jain, GR Watkins, GA Whitfield, MM Green, J Valle, MB Taylor, C Dickinson, PM Price, A Saleem. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 2010 Sep;22(7):570-7.